Left Atrial Appendage Closure Devices Market Analysis by 2030

The left atrial appendage closure devices market size is projected to grow from US$ 1195.40 million in 2022 to US$ 4870.64 million by 2030; it is projected to record a CAGR of 19.2% during 2022–2030.

Market Insights and Analyst View:

Left atrial appendage closure is a process that closes off the opening of the left atrial appendage. The left atrial appendage is a small pouch shaped like a windsock found in the heart's top left (the left atrium). The procedure is performed for the treatment of atrial fibrillation. In atrial fibrillation, the electrical impulses that control the heartbeat do not travel systematically through the heart. In this case, at the same time, many impulses begin and spread through the atria. The fast and chaotic impulses do not allow the atria to contract or squeeze blood into the ventricles effectively. The left atrial appendage (LAA) collects blood; because of its small size, the blood in the LAA and atria forms into clots, resulting in a higher risk of heart stroke. The LAA closure is a minimally invasive medical technique used to considerably reduce the risk of stroke in a patient having atrial fibrillation and for whom other methods of treatment have been unsuccessful and help eliminate the need to take blood-thinning medication. The increasing prevalence of atrial fibrillation and innovative product developments are expected to aid the left atrial appendage closure devices market growth.  Watchman Flx and Amplatzer Amulet are the two left atrial appendage closure devices approved for commercial use by the Food and Drug Administration.

Additionally, an aging population, hypertension-related diseases, and disrupted lifestyle activities such as smoking fuel market expansion. Moreover, increased awareness initiatives in untapped markets give growth opportunities throughout the forecast period. These factors are anticipated to propel the left atrial appendage closure device market growth.

Growth Drivers:

Atrial fibrillation is a common form of arrhythmia diagnosed in clinics and hospitals. According to the National Center for Biotechnology Information (NCBI), in February 2021, the prevalence of atrial fibrillation was 37,574 million cases worldwide. European-origin people are more likely to develop arrhythmia when compared with African Americans. Because the prevalence of cardiac arrhythmia increases with age, and women have a higher life expectancy than men, more women experience atrial fibrillation than men. Per the study conducted by the European Society of Cardiology in 2016, ~7.6 million people aged 65 or older had atrial fibrillation in the EU. The Society estimates that the number is anticipated to reach ~14.4 million by 2060. The prevalence of atrial fibrillation is predicted to reach 9.5% by 2060 from 7.8% in 2016.

The European Society of Cardiology also reported that atrial fibrillation is the most common arrhythmia, accounting for 0.28–2.6% of healthcare spending in European countries. Patients with atrial fibrillation are at a five-times higher risk of getting a stroke, and 20–30% of all stroke cases in the country are caused by atrial fibrillation. Similarly, according to the Centers for Disease Control and Prevention (CDC), it is anticipated that 12.1 million people in the US will have atrial fibrillation in 2030. Additionally, according to the CDC, it is estimated that 454,000 hospitalizations and diagnoses of atrial fibrillation are done in the US every year, and the condition contributes to 150,000 deaths yearly. There has been a significant demand for left atrial appendage closure devices in the industry due to the increasing prevalence of atrial fibrillation, one of the most difficult conditions requiring appendage treatment.

Moreover, as per the report by Biosense Webster, namely “Beyond the Burden: The Impact of Atrial Fibrillation in Asia Pacific,” published in 2019, ~16 million people in the Asia Pacific region suffer from atrial fibrillation, and the number is anticipated to reach ~72 million by 2050. Atrial fibrillation rates in international studies stated that an estimated 5.4% of Australian adults aged 55 and older had atrial fibrillation, and the condition affected ~500,000 people by 2020. Further, according to the Stroke Association report, about 1 million people suffer from atrial fibrillation in the UK, with half a million people having undiagnosed atrial fibrillation. Also, it is estimated that there are ~270,000 people aged over 65 in the UK suffering from undiagnosed (or silent) atrial fibrillation. The need for appendage treatment is due to the rising cases of atrial fibrillation. The increasing prevalence of atrial fibrillation, which is a major risk factor for stroke and heart-related complications, favors the adoption of left atrial appendage closure devices, driving the growth of the left atrial appendage (LAA) closure devices market.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Left Atrial Appendage Closure Devices Market: Strategic Insights

Market Size Value in	US$ 1195.40 million in 2022
Market Size Value by	US$ 4870.64 million by 2030
Growth rate	CAGR of 19.2% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The global left atrial appendage closure devices market is segmented based on technique, procedure, end-use, and geography. Based on technique, the market is segmented into epicardial and endocardial. Based on procedure, the market is bifurcated into percutaneous and surgical. Regarding end-use, the market is categorized into hospitals, ambulatory surgical centers, and others. The left atrial appendage closure devices market, based on geography, is segmented into North America (US, Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Segmental Analysis:

By technique, the left atrial appendage closure devices market is segmented into epicardial and endocardial. The endocardial segment held a significant share of the market in 2022 owing to safer, shorter hospital stays, more effective management of strokes, and reduced bleeding. The market share of endocardial LAA devices has also increased by the product pipeline, including the Watchman device, which has received US approval, and seven other devices that have also received the CE mark in Europe and are currently undergoing clinical trials

Left Atrial Appendage Closure Devices Market, by Technique – 2022 and 2030

Access Data

Based on the procedure, the left atrial appendage closure devices market is bifurcated into percutaneous and surgical. The surgical segment held a significant market share in 2022 due to the availability of various surgical approaches to LAA occlusion, such as suture exclusion and loops, stapler excision, and epicardial exclusion clips.

Based on end-use, the left atrial appendage closure devices market is categorized into hospitals, ambulatory surgical centers, and others. The hospitals segment held a significant share of the market in 2022.

Regional Analysis:

Based on geography, the left atrial appendage closure devices market is primarily divided into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa. North America captured a significant share of the global market in 2022. The left atrial appendage closure devices market growth in North America is attributed to well-developed healthcare infrastructure, increasing product development, technological advancements, a growing number of cases of atrial fibrillation, and the presence of major market players in the region. In 2022, the US held the region's largest market share. According to the CDC data released in October 2022, 12.1 million individuals in the US will have atrial fibrillation by 2030. According to a similar NCBI analysis released in July 2021, atrial fibrillation was diagnosed in 498 patients out of 8,686 patients in Mexico, with a higher prevalence in men and older women. The geriatric population in North America is also increasing. For example, Statistics Canada published data in August 2022 showing that the number of people aged 70-74 years in Canada was 1,847,585, while those aged 80-84 years stood at 840,545. The senior population's susceptibility to developing cardiovascular diseases will likely increase the demand for left atrial appendage closure devices. As this condition is likely to cause heart stroke, so left atrial appendage management is of utmost importance. The market for LAA closure devices is expected to continue to expand as new technologies are introduced into the market. Therefore, left atrial appendage closure devices are expected to be a major part of the market growth shortly.

Further, the increasing market players' strategies in this region to introduce innovative and technologically advanced left atrial appendage closure devices are expected to contribute to the market's growth. In August 2021, Abbott received approval from the Food and Drug Administration for its Amplatzer Amulet left atrial appendage occluder that helps in the treatment of people with atrial fibrillation who are at risk of stroke. The device provides immediate closure of the left atrial appendage, reducing the stroke’s risk and directly reducing the need for blood-thinning medication. Therefore, the above-mentioned factors are expected to contribute to the region's growth of the left atrial appendage closure devices market.

Industry Developments and Future Opportunities:

Several initiatives taken by key players operating in the global left atrial appendage (LAA) closure devices market are listed below:

• In June 2023, Conformal Medical, Inc. completed its Series D funding round, raising US$ 35 million. The company’s CLAAS system is designed to seal the left atrial appendage in patients with nonvalvular atrial fibrillation to decrease the risk of stroke without the need for anticoagulants.
• In November 2023, Medtronic is working on introducing a device in the US designed to close the left atrial appendage of the heart in patients undergoing cardiac surgery. The treatment is intended for patients who have atrial fibrillation that can lead to stroke.
• In June 2022, Conformal Medical, Inc., a medical device company developing next-generation left atrial appendage occlusion (LAAO) technology, announced the launch of the CONFORM pivotal trial with the registration of the first patients at two US sites. The investigational device exemption study evaluates the safety and efficacy of the company's CLAAS System compared to commercially available LAAO devices to support US Food and Drug Administration pre-market approval.

Competitive Landscape and Key Companies:

Some of the leading players operating in the left atrial appendage closure devices market are Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson Services Inc., Aegis Medical Group, AtriCure Inc., Lifetech Scientific Corporation, Lepu Medical Technology (Beijing) Co. Ltd., Cardia Inc., Occlutech International AB, and Medtronic. These companies focus on introducing new high-tech products, advancements in existing products, and geographic expansions to meet the rising consumer demand worldwide. Left atrial appendage closure devices market companies emphasize various growth strategies such as collaboration, product launches, expansions, and agreements, among others, to retain their position in the global market and increase their product range in specialty portfolios. They have a widespread global presence, which favors serving a large set of consumers and subsequently increases their left atrial appendage closure devices market share.